Stratton Management’s Teva Pharmaceuticals TEVA Stock Holding History

Stratton Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-7,500	Closed	-$467K	–	341
2015 Q1	$467K	Hold	7,500	–	–	0.02%	294
2014 Q4	$431K	Buy	+7,500	New	+$418K	0.02%	300
2014 Q3	–	Sell	-7,500	Closed	-$393K	–	341
2014 Q2	$393K	Hold	7,500	–	–	0.02%	307
2014 Q1	$396K	Hold	7,500	–	–	0.02%	294
2013 Q4	$301K	Sell	7,500 -350	-4%	-$13.8K	0.01%	313
2013 Q3	$297K	Buy	+7,850	New	+$306K	0.02%	313

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Stratton Management's TEVA Position: Q2 2015 in Review

Stratton Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 7,500 shares — an estimated $467K sold.

Stratton Management first reported a position in TEVA in Q3 2013 and held it in 6 quarters. The position peaked at $467K in Q1 2015. 818 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

Stratton Management reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Stratton Management sold 7,500 Teva Pharmaceuticals shares in Q2 2015, an estimated $467K.
Stratton Management first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 6 quarters.
Stratton Management's Teva Pharmaceuticals position peaked at $467K in Q1 2015.
818 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on Stratton Management's 13F filing for Q2 2015, filed 10 Aug 2015.